News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Sacituzumab govitecan proves real-world survival benefits in metastatic breast cancer
19 Jan 2026
byStephen Padilla
A real-world study of the antibody-drug conjugate (ADC) sacituzumab govitecan in patients with HR+/ HER2- metastatic breast cancer (mBC) or metastatic triple-negative breast cancer (mTNBC) shows consistent survival outcomes as those seen in clinical trials.
Sacituzumab govitecan proves real-world survival benefits in metastatic breast cancer
19 Jan 2026
Molecular analysis supports ibrutinib-venetoclax in poor-risk CLL patients
19 Jan 2026
byAudrey Abella
Findings from the phase III NCRI* FLAIR** trial demonstrate the benefit of MRD***-guided ibrutinib + venetoclax (I+V) in chronic lymphocytic leukaemia (CLL) patients with gene aberrations compared with ibrutinib and fludarabine, cyclophosphamide, and rituximab (FCR).







